PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022

Date: October 31, 2013
Pages: 312
Price:
US$ 10,995.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P1CC82CCFA3EN
Leaflet:

Download PDF Leaflet

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022

Summary

The lupus therapeutics market is dominated by generics and GlaxoSmithKline’s Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlysta’s launch, patients’ uptake has remained low, but due to its associated high price-tag Benlysta has managed to grow the lupus market in terms of value and is currently the second top-selling drug in this market, having generated approximately $107m in 2012 in the seven major markets. The top-selling drug in lupus in terms of value is Roche’s off-label Rituxan, which GlobalData estimates generated approximately $170m in 2012 in the seven major markets. There is high R&D activity for the development of new therapies for lupus and six promising biological therapies can potentially enter the SLE and LN market from 2017 to 2022. Anthera Pharmaceuticals, Eli Lilly and Merck Serono are developing anti-BLyS therapies. UCB’s epratuzumab is an anti-CD22, ImmuPharma’s Lupuzor is a CD4 T-cell modulator and Bristol-Myers Squibb’s Orencia is an anti-CD80/CD86 therapy. The introduction of new biologic drugs will shape the future competitive landscape and drive growth in the SLE and LN markets.

Highlights

Key Questions Answered
  • What was the impact of Benlysta on the lupus therapeutics market following its approval in 2011 and what is its future outlook within this market?
  • What do physicians think about Rituxan following its unsuccessful Phase III trials in LN, and how will it be used off-label in lupus during the forecast period?
  • What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in SLE and LN?
  • What are the unmet needs within the SLE and LN markets?
  • What are the remaining opportunities within the SLE and LN markets?
Key Findings
  • The main drivers of growth for the SLE and LN markets include the increasing uptake of biologics, the launch of Benlysta in Japan, the launch of new biologic drugs during the second half of the forecast period and the increasing number of prevalent cases of SLE and LN.
  • R&D strategies include the development of me-too and first-in-class therapies, partnerships and acquisitions, and the development of products for LN.
  • The lupus therapeutics market is characterized by significant unmet needs. The most pressing unmet need is the development of new therapies that will offer potent clinical benefits, have a positive safety profile and increase the available treatment options for patients.
  • With high R&D activity in the lupus therapeutics market, physicians are looking forward to pipeline products becoming available, which will enable them to improve patients’ treatment.
Scope
  • Overview of SLE and LN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized SLE and LN therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SLE and LN therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
  • Analysis of the current and future market competition in the global SLE and LN therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global SLE and LN therapeutics markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SLE and LN therapeutics markets in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global SLE and LN therapeutics markets from 2012-2022.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 DISEASE OVERVIEW

3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology
3.2 Prognosis
3.3 Quality of Life
3.4 Symptoms

4 EPIDEMIOLOGY

4.1 Risk Factors and Comorbidities
  4.1.1 Women are at a higher risk of developing SLE than men
  4.1.2 Caucasians are at lower risk of developing SLE than other ethnicities
  4.1.3 Familial history has been associated with an increased risk of developing SLE
  4.1.4 Certain occupational and environmental exposures trigger SLE
4.2 Global Trends
  4.2.1 US
  4.2.2 5EU
  4.2.3 Japan
4.3 Forecast Methodology
4.4 Sources Used
  4.4.1 US
  4.4.2 France
  4.4.3 Germany
  4.4.4 Italy
  4.4.5 Spain
  4.4.6 UK
  4.4.7 Japan
4.5 Sources Not Used
  4.5.1 US
  4.5.2 5EU
  4.5.3 Japan
4.6 Forecast Assumptions and Methods
  4.6.1 US
  4.6.2 5EU
  4.6.3 Japan
4.7 Epidemiological Forecast of SLE (2012-2022)
  4.7.1 Diagnosed Prevalent Cases of SLE
  4.7.2 Age-Specific Prevalent Cases of SLE
  4.7.3 Sex-Specific Prevalent Cases of Diagnosed SLE
  4.7.4 Age-Standardized Prevalence of SLE
  4.7.5 Diagnosed Prevalent Cases of LN
  4.7.6 Prevalent Cases of LN, Segmented by Class
4.8 Discussion
  4.8.1 Conclusions on Epidemiology Trends
  4.8.2 Limitations of the Analysis
  4.8.3 Strengths of the Analysis

5 DISEASE MANAGEMENT

5.1 Diagnosis Overview
  5.1.1 SLE Diagnosis
  5.1.2 LN Diagnosis
5.2 Treatment Overview
5.3 US
  5.3.1 Diagnosis
  5.3.2 Clinical Practice
5.4 France
  5.4.1 Diagnosis
  5.4.2 Clinical Practice
5.5 Germany
  5.5.1 Diagnosis
  5.5.2 Clinical Practice
5.6 Italy
  5.6.1 Diagnosis
  5.6.2 Clinical Practice
5.7 Spain
  5.7.1 Diagnosis
  5.7.2 Clinical Practice
5.8 UK
  5.8.1 Diagnosis
  5.8.2 Clinical Practice
5.9 Japan
  5.9.1 Diagnosis
  5.9.2 Clinical Practice

6 COMPETITIVE ASSESSMENT

6.1 Overview
6.2 Strategic Competitor Assessment
6.3 Product Profiles - Major Brands
  6.3.1 Antimalarial Therapy (numerous brand names)
  6.3.2 Steroids (numerous brand names)
  6.3.3 Methotrexate (numerous brand names)
  6.3.4 Mycophenolate Mofetil (numerous brand names)
  6.3.5 Cyclophosphamide (numerous brand names)
  6.3.6 Azathioprine (numerous brand names)
  6.3.7 Calcineurin Inhibitors (numerous brand names)
  6.3.8 Benlysta (belimumab)
  6.3.9 Rituxan (rituximab)
  6.3.10 Minor Therapeutic Classes

7 OPPORTUNITY AND UNMET NEED

7.1 Overview
7.2 Unmet Needs
  7.2.1 Efficacious Treatments with Reduced Side Effects
  7.2.2 Management of LN
  7.2.3 Improvement in Patients’ Mortality
  7.2.4 Management of Lupus Comorbidities
  7.2.5 Sensitive and Reliable Biomarkers
  7.2.6 Physicians’ Education and Public Awareness of SLE
  7.2.7 Unmet Needs Gap Analysis
7.3 Opportunities
  7.3.1 Efficacious and Safe Therapies
  7.3.2 Therapies Targeting LN Patients
  7.3.3 Treatments for Common Lupus Comorbidities
  7.3.4 Discovery of Biomarkers

8 PIPELINE ASSESSMENT

8.1 Overview
8.2 Clinical Trial Mapping
  8.2.1 Clinical Trials by Country
  8.2.2 Clinical Trials by Phase and Trial Status
8.3 Promising Drugs in Clinical Development
  8.3.1 Blisibimod (A-623)
  8.3.2 Tabalumab (LY-2127399)
  8.3.3 Atacicept
  8.3.4 Epratuzumab
  8.3.5 Lupuzor (rigerimod)
  8.3.6 Orencia (abatacept)

9 CURRENT AND FUTURE PLAYERS

9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
  9.3.1 GlaxoSmithKline
  9.3.2 Roche
  9.3.3 UCB
  9.3.4 Eli Lilly and Company
  9.3.5 Bristol-Myers Squibb
  9.3.6 Anthera Pharmaceuticals
  9.3.7 ImmuPharma
  9.3.8 Merck Serono

10 MARKET OUTLOOK

10.1 Global Markets
  10.1.1 Forecast
  10.1.2 Drivers and Barriers - Global Issues
10.2 US
  10.2.1 Forecast
  10.2.2 Key Events
  10.2.3 Drivers and Barriers
10.3 France
  10.3.1 Forecast
  10.3.2 Key Events
  10.3.3 Drivers and Barriers
10.4 Germany
  10.4.1 Forecast
  10.4.2 Key Events
  10.4.3 Drivers and Barriers
10.5 Italy
  10.5.1 Forecast
  10.5.2 Key Events
  10.5.3 Drivers and Barriers
10.6 Spain
  10.6.1 Forecast
  10.6.2 Key Events
  10.6.3 Drivers and Barriers
10.7 UK
  10.7.1 Forecast
  10.7.2 Key Events
  10.7.3 Drivers and Barriers
10.8 Japan
  10.8.1 Forecast
  10.8.2 Key Events
  10.8.3 Drivers and Barriers

11 APPENDIX

11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
  11.4.1 Diagnosed SLE and LN Patients
  11.4.2 Percent Drug-Treated Patients
  11.4.3 Drugs Included in Each Therapeutic Class
  11.4.4 Launch and Patent Expiry Dates
  11.4.5 General Pricing Assumptions
  11.4.6 Individual Drug Assumptions
  11.4.7 Generic Erosion
  11.4.8 Pricing of Pipeline Agents
11.5 Physicians and Specialists Included in this Study
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
  11.7.1 Analysts
  11.7.2 Epidemiologist
  11.7.3 Global Head of Healthcare
11.8 About GlobalData
11.9 Disclaimer

LIST OF FIGURES

Figure 1: Overview of the Etiology and Pathogenesis of SLE
Figure 2: Overview of the BAFF/APRIL Ligand and Receptor System
Figure 3: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, 2012-2022
Figure 4: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012
Figure 5: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, 2012
Figure 6: 7MM, Age-Standardized Prevalence (%) of Diagnosed SLE, All Ages, by Sex, 2012
Figure 7: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, 2012-2022
Figure 8: 6MM, Prevalent Cases of LN, by Class, All Ages, Both Sexes, 2012
Figure 9: Overview of the Treatment Management of SLE
Figure 10: SLE and LN Therapeutics - Clinical Trials by Country, 2013
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2012-2022
Figure 12: Company Portfolio Gap Analysis in SLE and LN, 2012-2022
Figure 13: Global Sales for SLE and LN by Region, 2012-2022
Figure 14: Sales for SLE in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022
Figure 15: Sales for LN in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022
Figure 16: Sales for SLE and LN in the US by Drug Class, 2012-2022
Figure 17: Sales for SLE and LN in France by Drug Class, 2012-2022
Figure 18: Sales for SLE and LN in Germany by Drug Class, 2012-2022
Figure 19: Sales for SLE and LN in Italy by Drug Class, 2012-2022
Figure 20: Sales for SLE and LN in Spain by Drug Class, 2012-2022
Figure 21: Sales for SLE and LN in the UK by Drug Class, 2012-2022
Figure 22: Sales for SLE and LN in Japan by Drug Class, 2012-2022

COMPANIES MENTIONED

GlaxoSmithKline
Roche
UCB
Eli Lilly and Company
Bristol-Myers Squibb
Anthera Pharmaceuticals
ImmuPharma
Merck Serono

UCB's epratuzumab is the most promising drug in the late-stage lupus therapeutics pipeline, and GlobalData estimates its launch in the US and EU will be in 2017 and in Japan in 2019. With its novel MOA and positive clinical trial efficacy and safety data to date, key opinion leaders (KOLs) are excited about this agent that can potentially be more effective than GlaxoSmithKline's Benlysta, as well as provide benefit to more patients with lupus. The frequent intravenous administration dosing regimen of this therapy remains a major concern, and a key opportunity for the product will be exploring a subcutaneous formulation.

Bristol-Myers Squibb's Orencia has the potential to be a promising drug for LN if clinical trials demonstrate efficacy in this patient segment. Although GlobalData and KOLs anticipate the clinical benefits to be mild from this therapy, its uptake will mainly be driven by the significant unmet need for available treatments for the management of patients with LN.

Eli Lilly's tabalumab binds both soluble and membrane-bound BLyS (also known as BAFF) and it is hypothesized that it can show superior clinical efficacy to GlaxoSmithKline's Benlysta. Tabalumab will be available for subcutaneous administration and will directly compete with Benlysta. It remains to be seen if tabalumab is a superior product to Benlysta, which will subsequently determine its uptake and eventual commercial success.

Anthera Pharmaceutical's blisibimod, similarly to Eli Lilly’s tabalumab, is a biologic drug which binds to both soluble and membrane-bound BLyS and will be available for subcutaneous administration. Blisibimod will directly compete with GlaxoSmithKline’s Benlysta, and its uptake and eventual commercial success will be determined by its ability to demonstrate clinical superiority to Benlysta, and more importantly by Anthera entering into successful partnerships, which will be vital for progressing the clinical development of this product.

The material was prepared in March, 2014.

LIST OF TABLES

Table 1: Symptoms of SLE
Table 2: Risk Factors Associated with SLE
Table 3: World Health Organization Morphologic Classification of Lupus Nephritis (Modified in 1982)
Table 4: Sources of Prevalence Data Used in this Analysis
Table 5: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, Select Years 2012-2022
Table 6: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012
Table 7: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, by Sex, N, Row (%), 2012
Table 8: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, Select Years 2012-2022
Table 9: 6MM, Prevalent Cases in the Different Classes of LN, All Age, Both Sexes, N, Row (%), 2012
Table 10: 1997 Updated ACR Criteria for Classification of SLE
Table 11: The SLICC Clinical and Immunologic Criteria for Classification of SLE
Table 12: WHO and ISN/RPS classifications of LN
Table 13: Treatment Guidelines for SLE and LN
Table 14: Most Prescribed Drugs for SLE and LN by Class in the Global Markets, 2013
Table 15: Leading Treatments for SLE and LN, 2013
Table 16: Product Profile - Hydroxychloroquine
Table 17: Antimalarial Therapy SWOT Analysis, 2013
Table 18: Global SLE Sales Forecasts ($m) for Antimalarial Therapy, 2012-2022
Table 19: Global LN Sales Forecasts ($m) for Antimalarial Therapy, 2012-2022
Table 20: Product Profile - Steroids
Table 21: Steroids SWOT Analysis, 2013
Table 22: Global SLE Sales Forecasts ($m) for Steroid Therapy, 2012-2022
Table 23: Global LN Sales Forecasts ($m) for Steroid Therapy, 2012-2022
Table 24: Product Profile - Methotrexate
Table 25: Methotrexate SWOT Analysis, 2013
Table 26: Global SLE Sales Forecasts ($m) for Methotrexate, 2012-2022
Table 27: Global LN Sales Forecasts ($m) for Methotrexate, 2012-2022
Table 28: Product Profile - Mycophenolate Mofetil
Table 29: Mycophenolate Mofetil SWOT Analysis, 2013
Table 30: Global SLE Sales Forecasts ($m) for Mycophenolate Mofetil, 2012-2022
Table 31: Global LN Sales Forecasts ($m) for Mycophenolate Mofetil, 2012-2022
Table 32: Product Profile - Cyclophosphamide
Table 33: Cyclophosphamide SWOT Analysis, 2013
Table 34: Global SLE Sales Forecasts ($m) for Cyclophosphamide, 2012-2022
Table 35: Global LN Sales Forecasts ($m) for Cyclophosphamide, 2012-2022
Table 36: Product Profile - Azathioprine
Table 37: Azathioprine SWOT Analysis, 2013
Table 38: Global SLE Sales Forecasts ($m) for Azathioprine, 2012-2022
Table 39: Global LN Sales Forecasts ($m) for Azathioprine, 2012-2022
Table 40: Product Profile - Calcineurin Inhibitors
Table 41: Calcineurin Inhibitors SWOT Analysis, 2013
Table 42: Global SLE Sales Forecasts ($m) for Calcineurin Inhibitors, 2012-2022
Table 43: Global LN Sales Forecasts ($m) for Calcineurin Inhibitors, 2012-2022
Table 44: Product Profile - Benlysta
Table 45: Benlysta SWOT Analysis, 2013
Table 46: Global SLE Sales Forecasts ($m) for Benlysta, 2012-2022
Table 47: Global LN Sales Forecasts ($m) for Benlysta, 2012-2022
Table 48: Product Profile - Rituxan
Table 49: Rituxan SWOT Analysis, 2013
Table 50: Global SLE Sales Forecasts ($m) for Rituxan, 2012-2022
Table 51: Global LN Sales Forecasts ($m) for Rituxan, 2012-2022
Table 52: Summary of Minor Therapeutic Classes in SLE and LN, 2013
Table 53: Overall Unmet Needs in SLE and LN - Current Level of Attainment
Table 54: Clinical Unmet Needs in SLE and LN - Gap Analysis, 2013
Table 55: SLE and LN - Clinical Trials by Phase and Status, 2013
Table 56: SLE and LN - Phase Pipeline, 2013
Table 57: Comparison of Therapeutic Classes in Development for SLE and LN, 2013
Table 58: Product Profile - Blisibimod
Table 59: Blisibimod SWOT Analysis, 2013
Table 60: Global SLE Sales Forecasts ($m) for Blisibimod, 2012-2022
Table 61: Global LN Sales Forecasts ($m) for Blisibimod, 2012-2022
Table 62: Product Profile - Tabalumab (LY-2127399)
Table 63: Tabalumab SWOT Analysis, 2013
Table 64: Global SLE Sales Forecasts ($m) for Tabalumab, 2012-2022
Table 65: Global LN Sales Forecasts ($m) for Tabalumab, 2012-2022
Table 66: Product Profile - Atacicept
Table 67: Atacicept SWOT Analysis, 2013
Table 68: Global SLE Sales Forecasts ($m) for Atacicept, 2012-2022
Table 69: Global LN Sales Forecasts ($m) for Atacicept, 2012-2022
Table 70: Product Profile - Epratuzumab
Table 71: Epratuzumab SWOT Analysis, 2013
Table 72: Global SLE Sales Forecasts ($m) for Epratuzumab, 2012-2022
Table 73: Global LN Sales Forecasts ($m) for Epratuzumab, 2012-2022
Table 74: Product Profile - Lupuzor
Table 75: Lupuzor SWOT Analysis, 2013
Table 76: Global SLE Sales Forecasts ($m) for Lupuzor, 2012-2022
Table 77: Global LN Sales Forecasts ($m) for Lupuzor, 2012-2022
Table 78: Product Profile - Orencia
Table 79: Orencia SWOT Analysis, 2013
Table 80: Global SLE Sales Forecasts ($m) for Orencia, 2012-2022
Table 81: Global LN Sales Forecasts ($m) for Orencia, 2012-2022
Table 82: Key Companies in the SLE and LN Market, 2013
Table 83: GlaxoSmithKline’s SLE and LN Portfolio Assessment, 2013
Table 84: GlaxoSmithKline SWOT Analysis, 2013
Table 85: Roche’s SLE and LN Portfolio Assessment, 2013
Table 86: Roche SWOT Analysis, 2013
Table 87: UCB’s SLE and LN Portfolio Assessment, 2013
Table 88: UCB SWOT Analysis, 2013
Table 89: Eli Lilly and Company’s SLE and LN Portfolio Assessment, 2013
Table 90: Eli Lilly and Company SWOT Analysis, 2013
Table 91: BMS’ SLE and LN Portfolio Assessment, 2013
Table 92: BMS SWOT Analysis, 2013
Table 93: Anthera Pharmaceuticals’ SLE and LN Portfolio Assessment, 2013
Table 94: Anthera Pharmaceuticals SWOT Analysis, 2013
Table 95: ImmuPharma’s SLE and LN Portfolio Assessment, 2013
Table 96: ImmuPharma SWOT Analysis, 2013
Table 97: Merck Serono’s SLE and LN Portfolio Assessment, 2013
Table 98: Merck Serono SWOT Analysis, 2013
Table 99: Global Sales Forecasts ($m) for SLE, 2012-2022
Table 100: Global Sales Forecasts ($m) for LN, 2012-2022
Table 101: SLE and LN Market - Global Drivers and Barriers, 2012-2022
Table 102: Sales Forecasts ($m) for SLE in the US, 2012-2022
Table 103: Sales Forecasts ($m) for LN in the US, 2012-2022
Table 104: Key Events Impacting Sales for SLE and LN in the US, 2012-2022
Table 105: SLE and LN Market in the US - Drivers and Barriers, 2012-2022
Table 106: Sales Forecasts ($m) for SLE in France, 2012-2022
Table 107: Sales Forecasts ($m) for LN in France, 2012-2022
Table 108: Key Events Impacting Sales for SLE and LN in France, 2012-2022
Table 109: SLE and LN Market in France - Drivers and Barriers, 2012-2022
Table 110: Sales Forecasts ($m) for SLE in Germany, 2012-2022
Table 111: Sales Forecasts ($m) for LN in Germany, 2012-2022
Table 112: Key Events Impacting Sales for SLE and LN in Germany, 2012-2022
Table 113: SLE and LN Market in Germany - Drivers and Barriers, 2012-2022
Table 114: Sales Forecasts ($m) for SLE in Italy, 2012-2022
Table 115: Sales Forecasts ($m) for LN in Italy, 2012-2022
Table 116: Key Events Impacting Sales for SLE and LN in Italy, 2012-2022
Table 117: SLE and LN Market in Italy - Drivers and Barriers, 2012-2022
Table 118: Sales Forecasts ($m) for SLE in Spain, 2012-2022
Table 119: Sales Forecasts ($m) for LN in Spain, 2012-2022
Table 120: Key Events Impacting Sales for SLE and LN in Spain, 2012-2022
Table 121: SLE and LN Market in Spain - Drivers and Barriers, 2012-2022
Table 122: Sales Forecasts ($m) for SLE in the UK, 2012-2022
Table 123: Sales Forecasts ($m) for LN in the UK, 2012-2022
Table 124: Key Events Impacting Sales for SLE and LN in the UK, 2012-2022
Table 125: SLE and LN Market in the UK - Drivers and Barriers, 2012-2022
Table 126: Sales Forecasts ($m) for SLE in Japan, 2012-2022
Table 127: Sales Forecasts ($m) for LN in Japan, 2012-2022
Table 128: Key Events Impacting Sales for SLE and LN in Japan, 2012-2022
Table 129: SLE and LN Market in Japan - Drivers and Barriers, 2012-2022
Table 130: Key Launch Dates
Table 131: Key Patent Expiries
Table 132: Number of Physicians Surveyed by Country

Ask Your Question

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: